Village Farms(VFF) - 2024 Q3 - Quarterly Report

Canadian Cannabis Segment Performance - Canadian Cannabis segment achieved the number one market share in Quebec and maintained the number one market share in Ontario[54] - Canadian Cannabis segment saw year-over-year increases in international medicinal sales to Australia, Germany, and the United Kingdom for Q3 and year-to-date 2024[54] - Canadian Cannabis segment launched Neon Lambo cultivar in Q4 2024 with strong reception and plans new category launches through Q4 2024 and Q1 2025[54] - Canadian Cannabis net sales increased by 27% to $36,463 for the three months ended September 30, 2024, compared to$28,810 in the same period in 2023, driven by an 18% increase in branded sales and a 66% increase in non-branded sales[75] - Canadian Cannabis net sales for the nine months ended September 30, 2024, increased by 40% to $114.654 million, driven by a 30$1.168 million, down from 2.863 million in Q3 2023, primarily due to higher tax provisions and increased SG&A expenses[83] - Adjusted EBITDA for Canadian Cannabis in Q3 2024 was 4.752 million, slightly up from $4.585 million in Q3 2023[84] - Adjusted EBITDA for Canadian Cannabis for the nine months ended September 30, 2024, was$13.643 million, compared to $13.273 million in the same period in 2023[92] - International sales in the Canadian Cannabis segment increased by 94$57.193 million for the nine months ended September 30, 2024, due to higher branded sales volume[89] - No impairment indicators for Canadian Cannabis as of September 30, 2024 and September 30, 2023[129] U.S. Cannabis Segment Performance - U.S. Cannabis segment selected as one of 25 participants for the DEA's upcoming hearing on marijuana rescheduling, expected in January or February 2025[55] - U.S. Cannabis net sales for Q3 2024 decreased by 21% to $3.943 million, primarily due to new CBD sales restrictions and lower direct-to-consumer sales[93] - U.S. Cannabis gross profit for Q3 2024 was$2.500 million, with a gross margin of 63%, down from $3.185 million and a 64$2,489 (16%) to $12,777 compared to$15,266 for the same period in 2023, primarily due to new restrictions on CBD sales in eight states and competition from unregulated hemp-derived products[98] - U.S. Cannabis gross profit for the nine months ended September 30, 2024 decreased by $2,157 to$7,824 (61% gross margin) compared to $9,981 (65$13,173), significantly higher than the net loss of ($125) in 2023, primarily due to a 2024 impairment charge of ($11,939) and lower sales at a reduced gross margin[100] - The company recognized a goodwill and intangible asset impairment of $11,939 in the U.S. Cannabis segment due to recent historical performance and near-term forecasts[75] - The U.S. Cannabis segment's fair value was determined using a discounted cash flow projection with an average revenue growth rate of 6$10,039 recorded due to fair value being lower than carrying amount as of June 30, 2024[128] - Impairment charge to brand intangible of $1,900 allocated due to fair value being lower than carrying value of$1,900 as of June 30, 2024[128] VF Fresh (Produce) Segment Performance - VF Fresh (Produce) segment implemented new cultivation technologies, including artificial intelligence, to drive operational improvements[55] - VF Fresh sales for the three months ended September 30, 2024 increased by $7,058 (20$42,770 compared to $35,712 in 2023, driven by a 25$3,481 (8% gross margin) compared to $1,492 (4$376, a significant improvement from a net loss of ($951) in 2023, driven by higher sales volume and stronger gross margins[106] - VF Fresh sales for the nine months ended September 30, 2024 increased by$11,758 (10%) to $125,883 compared to$114,125 in 2023, primarily due to a 12% increase in pounds sold and higher supply partner average selling prices[108] - VF Fresh gross profit for the nine months ended September 30, 2024 improved to $2,627 (2$654) (-1% gross margin) in 2023, driven by increased sales and lower costs per pound[110] - VF Fresh net loss for the nine months ended September 30, 2024 was ($7,810), compared to a net loss of ($4,268) in 2023, primarily due to the absence of a $5,584 legal settlement benefit recorded in 2023[112] Village Farms Clean Energy Segment Performance - Village Farms Clean Energy's Delta RNG Project began operations in April 2024, contributing incremental profit to the company[56] - Village Farms Clean Energy produced net income of$0.3 million in Q3 2024 through royalty payments from its clean energy partner[56] Financial Performance Overview - Sales for the three months ended September 30, 2024 increased by $13,858 (20$83,368 compared to $69,510 in the same period in 2023, driven by growth in Canadian Cannabis and VF Fresh sales[66] - Gross profit for the three months ended September 30, 2024 increased by$1,087 (7%) to $15,708 compared to$14,621 in the same period in 2023, primarily due to higher gross profit at VF Fresh[66] - Adjusted EBITDA for the three months ended September 30, 2024 improved to $5,302 compared to$3,248 in the same period in 2023, driven by stronger performance from VF Fresh[70] - Sales for the nine months ended September 30, 2024 increased by $42,249 (20$253,627 compared to $211,378 in the same period in 2023, driven by growth in Canadian Cannabis and VF Fresh sales[70] - Gross profit for the nine months ended September 30, 2024 increased by$2,049 (5%) to $40,469 compared to$38,420 in the same period in 2023, primarily due to higher gross profit at VF Fresh and Canadian Cannabis[70] - Adjusted EBITDA for the nine months ended September 30, 2024 decreased by $2,909 to$5,334 compared to $8,243 in the same period in 2023, mainly due to the inclusion of the ToBRFV Legal Settlement in 2023 and higher selling, general, and administrative costs in 2024[72] - Interest expense for the three months ended September 30, 2024 decreased by$204 (21%) to $784 compared to$988 in the same period in 2023, due to a decrease in the average outstanding debt balance[62] - Interest expense for the nine months ended September 30, 2024 decreased by $926 (26$2,606 compared to $3,532 in the same period in 2023, due to a decrease in the average outstanding debt balance[68] - Loss before taxes for the three months ended September 30, 2024 decreased by$2,261 to $656 compared to$2,917 in the same period in 2023, primarily due to improved gross margins and a foreign currency gain[65] - Loss before taxes for the nine months ended September 30, 2024 increased by $17,273 (191$26,313 compared to $9,040 in the same period in 2023, primarily due to an impairment of goodwill and intangible assets in the U.S. Cannabis segment[70] - Total sales for the three months ended September 30, 2024, were$83,368, with Fresh Produce contributing $42,770, Cannabis Canada$36,463, Cannabis U.S. $3,943, and Clean Energy$192[73] - Adjusted EBITDA for the three months ended September 30, 2024, was $5,302, with Cannabis Canada contributing$4,752, Fresh Produce $2,331, and Clean Energy$313[73] - Total sales for the nine months ended September 30, 2024, were $253,627, with Fresh Produce contributing$125,883, Cannabis Canada $114,654, Cannabis U.S.$12,777, and Clean Energy $313[75] - Adjusted EBITDA for the nine months ended September 30, 2024, was$5,334, with Cannabis Canada contributing $13,643, Fresh Produce ($1,991), and Clean Energy $354[75] - Net loss for the nine months ended September 30, 2024, was$27,221, with Cannabis Canada contributing $3,399, Fresh Produce ($7,810), and Cannabis U.S. ($13,173)[75] - Basic and diluted loss per share for the nine months ended September 30, 2024, was$0.25[75] - Total sales for the company reached $211.378 million, with Fresh Produce contributing$114.125 million, Cannabis Canada $81.987 million, and Cannabis U.S.$15.266 million[76] - Sales for the three months ended September 30, 2024, increased by 20% to $83.368 million compared to$69.510 million in 2023[125] - Adjusted EBITDA for the three months ended September 30, 2024, increased by 63% to $5.302 million compared to$3.248 million in 2023[125] - Sales for the nine months ended September 30, 2024, increased by 20% to $253.627 million compared to$211.378 million in 2023[126] - Adjusted EBITDA for the nine months ended September 30, 2024, decreased by 35% to $5.334 million compared to$8.243 million in 2023[126] - Cost of sales for the nine months ended September 30, 2024, increased by 23% to $213.158 million compared to$172.958 million in 2023[126] - Selling, general, and administrative expenses for the nine months ended September 30, 2024, increased by 5% to $52.593 million compared to$49.980 million in 2023[126] - Net income for the three months ended September 30, 2024, was a loss of $820 thousand, with significant contributions from Cannabis Canada ($1,168 thousand) and Clean Energy ($297 thousand), offset by losses in Cannabis U.S. ($192 thousand) and Corporate ($2,469 thousand)[121] - Adjusted EBITDA for the three months ended September 30, 2024, was$5.302 million, driven by strong performance in Cannabis Canada ($4.752 million) and Fresh Produce ($2.331 million), despite losses in Cannabis U.S. ($159 thousand) and Corporate ($1.935 million)[121] - For the nine months ended September 30, 2024, the company reported a net loss of $27.221 million, with Cannabis Canada contributing$3.399 million in income, while Fresh Produce and Corporate reported losses of $7.810 million and$9.975 million, respectively[122] - Adjusted EBITDA for the nine months ended September 30, 2024, was $5.334 million, with Cannabis Canada contributing$13.643 million, offset by losses in Fresh Produce ($1.991 million), Cannabis U.S. ($1.014 million), and Corporate ($5.658 million)[122] - Net loss for the three months ended September 30, 2023, was$1.299 million, with Cannabis Canada generating $2.863 million in income, while Fresh Produce and Corporate reported losses of$951 thousand and $3.232 million, respectively[123] - Adjusted EBITDA for the three months ended September 30, 2023, was$3.248 million, with Cannabis Canada contributing $4.585 million, offset by losses in Fresh Produce ($774 thousand), Clean Energy ($57 thousand), and Corporate ($2.275 million)[123] - Net loss for the nine months ended September 30, 2023, was $9.315 million, with a total adjusted EBITDA of$8.243 million[124] Financial Position and Liquidity - As of September 30, 2024, the company had cash and cash equivalents of $28,696 and working capital of$65,441, compared to $35,291 and$79,612, respectively, at December 31, 2023[114] - FCC Term Loan balance was $21,312 on September 30, 2024, down from$22,788 on December 31, 2023, with an interest rate of 8.81% per annum[116] - Operating Loan had an outstanding balance of $4,000 and future availability of$4,556 on September 30, 2024[116] - PSF Non-Revolving Facility outstanding amount was $7,028 on September 30, 2024, down from$8,298 on December 31, 2023, with an interest rate of 8.45%[117] - PSF Term Loan outstanding amount was $11,560 on September 30, 2024, down from$13,201 on December 31, 2023, with an interest rate of 8.45%[117] - BDC Credit Facility outstanding amount was $3,353 on September 30, 2024, down from$3,771 on December 31, 2023, with an interest rate of 10.20%[117] - Cash provided by operating activities for the nine months ended September 30, 2024 was $9,936, compared to$6,805 for the same period in 2023[117] - Cash used in investing activities for the nine months ended September 30, 2024 was ($8,227), primarily due to capital expenditures for the Netherlands-based cannabis production facility[117] - Cash used in financing activities for the nine months ended September 30, 2024 was ($8,118), including debt repayments of ($4,301) and acquisitions of additional ownership interests in Rose LifeScience and Leli[117] - Net cash decrease for the nine months ended September 30, 2024 was ($6,409), compared to a net cash increase of $18,842 for the same period in 2023[118] Market and Regulatory Developments - The company received notification from Nasdaq regarding non-compliance with the minimum bid price requirement, with a compliance deadline of April 16, 2025[56] - Leli Holland completed construction of its first indoor cultivation facility in Drachten, Netherlands, with cultivation beginning in October 2024 and first sales expected in Q1 2025[56] - Company monitors foreign exchange risk and matches sales and vendor payments to minimize net impact[131] - No material changes to market risks other than interest rate and foreign exchange risks[131]